George Fennell Sells 9,986 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

IDEXX Laboratories Trading Down 1.4 %

Shares of IDXX stock opened at $457.35 on Thursday. The stock’s 50-day moving average price is $429.67 and its 200-day moving average price is $453.23. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The stock has a market capitalization of $37.45 billion, a price-to-earnings ratio of 42.86, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research reports. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday. Finally, Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

Hedge Funds Weigh In On IDEXX Laboratories

Several institutional investors have recently bought and sold shares of the business. ExodusPoint Capital Management LP purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $23,067,000. Motley Fool Asset Management LLC grew its stake in IDEXX Laboratories by 13.4% in the fourth quarter. Motley Fool Asset Management LLC now owns 4,456 shares of the company’s stock valued at $1,842,000 after purchasing an additional 526 shares during the last quarter. Cynosure Group LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $1,831,000. Cinctive Capital Management LP boosted its holdings in IDEXX Laboratories by 18.7% in the fourth quarter. Cinctive Capital Management LP now owns 3,942 shares of the company’s stock worth $1,630,000 after acquiring an additional 622 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $2,365,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.